Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for Curevac?
Curevac's Earnings Per Share (EPS) over the trailing twelve months (TTM) is 0.719. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Curevac's stock?
Currently, 1 analysts cover Curevac's stock, with a consensus target price of €4.647. Analyst ratings provide insights into the stock's expected performance.
What is Curevac's revenue over the trailing twelve months?
Over the trailing twelve months, Curevac reported a revenue of €81.04M.
What is the EBITDA for Curevac?
Curevac's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -€170.72M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Curevac?
Curevac has a free cash flow of -€143.00M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Curevac have, and what sector and industry does it belong to?
Curevac employs approximately 983 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Curevac's shares?
The free float of Curevac is 221.56M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- EPS (TTM)
- 0.719
- Free Float
- 221.56M
- Revenue (TTM)
- €81.04M
- EBITDA (TTM)
- -€170.72M
- Free Cashflow (TTM)
- -€143.00M
Analyst Ratings
The price target is €4.647 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
- Employees
- 983
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- NL0015436031
- Primary Ticker
- CVAC
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet